Iatrogenic Creutzfeldt–Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?

Suzanne L Solvyns and David W Ralston
Med J Aust 2011; 194 (4): . || doi: 10.5694/j.1326-5377.2011.tb03793.x
Published online: 21 February 2011

To the Editor: Although we welcome Boyd and colleagues’ recommendations for changes to infection control guidelines for Australian recipients of human growth hormone (hGH) and human pituitary gonadotrophin (hPG),1 we are concerned about the accuracy of the history provided and do not want it misrepresented.

  • Suzanne L Solvyns
  • David W Ralston

  • CJD Support Group Network, Sydney, NSW.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.